There is no new clinical data (maybe real world evidence that we aren't privy to) which is what MSB said it would gather the previous two CRLs.
Maybe the FDA has changed its mind, which would be great for MSB.
None of that is wrong, it's the truth.
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-93
-
- There are more pages in this discussion • 1,004 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
93.5¢ |
Change
0.020(2.19%) |
Mkt cap ! $1.067B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 94.5¢ | 92.0¢ | $1.622M | 1.742M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 64563 | 93.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.0¢ | 204239 | 3 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |